Bellevue Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-19,046
| Closed | -$549K | – | 161 |
|
|
2024
Q3 | $549K | Sell |
19,046
-425,358
| -96% | -$12.3M | 0.01% | 127 |
|
|
2024
Q2 | $17M | Sell |
444,404
-29,511
| -6% | -$1.13M | 0.28% | 80 |
|
|
2024
Q1 | $27.9M | Sell |
473,915
-347,885
| -42% | -$20.4M | 0.42% | 67 |
|
|
2023
Q4 | $49.2M | Buy |
821,800
+27,959
| +4% | +$1.67M | 0.75% | 43 |
|
|
2023
Q3 | $30.2M | Buy |
793,841
+275,346
| +53% | +$10.5M | 0.49% | 60 |
|
|
2023
Q2 | $47.2M | Sell |
518,495
-590,887
| -53% | -$53.8M | 0.67% | 50 |
|
|
2023
Q1 | $73.2M | Buy |
1,109,382
+5,165
| +0.5% | +$341K | 1.06% | 31 |
|
|
2022
Q4 | $57.1M | Buy |
1,104,217
+96,773
| +10% | +$5M | 0.76% | 40 |
|
|
2022
Q3 | $68.8M | Sell |
1,007,444
-198,978
| -16% | -$13.6M | 0.99% | 36 |
|
|
2022
Q2 | $54.6M | Buy |
1,206,422
+107,710
| +10% | +$4.87M | 0.77% | 43 |
|
|
2022
Q1 | $55.8M | Buy |
1,098,712
+448,121
| +69% | +$22.8M | 0.65% | 53 |
|
|
2021
Q4 | $30.8M | Buy |
650,591
+602,591
| +1,255% | +$28.5M | 0.32% | 85 |
|
|
2021
Q3 | $1.58M | Hold |
48,000
| – | – | 0.02% | 154 |
|
|
2021
Q2 | $3.03M | Hold |
48,000
| – | – | 0.03% | 138 |
|
|
2021
Q1 | $2.06M | Hold |
48,000
| – | – | 0.02% | 142 |
|
|
2020
Q4 | $2.75M | Buy |
+48,000
| New | +$2.75M | 0.03% | 135 |
|
|
2020
Q2 | – | Sell |
-29,900
| Closed | -$801K | – | 209 |
|
|
2020
Q1 | $801K | Buy |
+29,900
| New | +$801K | 0.02% | 145 |
|